Gilead Anti-Hep-C Treatment on the FDA Fast Track

Gilead Anti-Hep-C Treatment on the FDA Fast Track

Gilead Sciences has received FDA priority review status for its New Drug Application for sofosbuvir, the company announced Friday. Sofosbuvir is a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

10
Like
Save

Comments

Write a comment

*